Treace Medical Concepts Earnings Preview: What to Expect Soon
Treace Medical Concepts (NASDAQ: TMCI) is set to unveil its quarterly earnings report shortly. Investors are keenly anticipating this release with hopes that it will surpass estimates and provide a positive outlook for the coming quarter. Analysts have forecasted an earnings per share (EPS) of $-0.27 for the upcoming report.
This state of anticipation is critical as it can significantly influence stock prices. New investors should remember that market sentiment often leans towards future projections rather than solely reflecting past performance.
Overview of Past Earnings
In the last quarter, Treace Medical Concepts faced a challenge, reporting an EPS lower than forecasts by $0.05, which resulted in a 2.4% drop in its share price the next day. Such market reactions are critical for long-term shareholders to acknowledge.
A dive into the past performances reveals significant fluctuations in Treace Medical Concepts’s earnings:
- Q2 2024: Estimated EPS: -0.29, Actual EPS: -0.34, Price change: -2.0%
- Q1 2024: Estimated EPS: -0.3, Actual EPS: -0.3, Price change: -62.0%
- Q4 2023: Estimated EPS: -0.09, Actual EPS: -0.1, Price change: -6.0%
- Q3 2023: Estimated EPS: -0.26, Actual EPS: -0.28, Price change: -38.0%
Performance of Treace Medical Concepts Shares
As of November 1, shares of Treace Medical Concepts are trading around $4.78. This marks a significant decrease of approximately 50.9% over the last year. The negative returns could leave long-term shareholders feeling anxious as they look forward to the upcoming earnings announcement.
Analyst Insights on Treace Medical Concepts
Understanding the prevailing market sentiment and forecasts can be essential for stakeholders. According to analysts, Treace Medical Concepts holds a consensus rating of Neutral based on three ratings, with an average one-year price target of $6.83, suggesting a promising potential upside of around 42.89%.
Analyzing Ratings Among Peers
When considering Treace Medical Concepts alongside its peers—Tactile Systems Tech, ClearPoint Neuro, and Delcath Systems—you can gain insight into their competitive positioning:
- Tactile Systems Tech has an analyst consensus rating of Buy, with a projected price target of $23.0, revealing an impressive potential upside of 381.17%.
- ClearPoint Neuro also has a Buy rating with a target price of $15.0, indicating a good upside of 213.81%.
- Delcath Systems carries a Buy consensus, with a target of $22.5, presenting an upside of 370.71%.
Analysis Summary for Peers
A comparative analysis of key metrics reveals Treace Medical Concepts struggles in revenue growth and gross profit, ranking at the bottom relative to its peers. Such metrics are pivotal for stakeholders to consider when assessing the company’s market standing.
Summarizing key metrics:
- Treace Medical Concepts: Revenue Growth: 5.96%, Gross Profit: $35.67M, Return on Equity: -17.78%
- Tactile Systems Tech: Revenue Growth: 7.14%, Gross Profit: $54.10M, Return on Equity: 2.18%
- ClearPoint Neuro: Revenue Growth: 32.07%, Gross Profit: $4.99M, Return on Equity: -13.21%
- Delcath Systems: Revenue Growth: 1468.89%, Gross Profit: $6.25M, Return on Equity: -146.09%
Discovering Treace Medical Concepts: A Closer Look
Treace Medical Concepts Inc is an innovative company in the orthopaedic medical device sector, concentrating on enhancing surgical solutions for bunion deformities. The Lapiplasty 3D Bunion Correction procedure stands out as it comprehensively addresses the underlying issues of bunion deformities and promotes quick recovery for patients. This unique focus sets Treace Medical Concepts apart in a competitive landscape.
Financial Milestones: Treace Medical Concepts's Journey
Market Capitalization: Treace Medical's market capitalization remains below industry averages, potentially limiting its expansion and investment capacity.
Revenue Growth: The company has recorded a revenue growth of 5.96% for the recent quarter ending June 30, 2024, but this is still below what is typical in the Health Care sector.
Net Margin: Treace Medical Concepts demonstrates a net margin of -47.7%, pointing to areas for operational improvement and cost efficiency.
Return on Equity (ROE): The company's ROE, at -17.78%, reflects potential concerns about utilizing equity capital effectively.
Return on Assets (ROA): With an ROA of -9.05%, Treace Medical Concepts may find it challenging to extract optimal returns from asset investments.
Debt Management: Favorably, Treace Medical Concepts showcases a debt-to-equity ratio of 0.62, highlighting a strong financial position relative to industry norms.
Frequently Asked Questions
What is the expected EPS for Treace Medical Concepts?
The expected EPS for Treace Medical Concepts is $-0.27 for the upcoming earnings report.
How did Treace Medical Concepts perform last quarter?
Last quarter, Treace Medical Concepts reported an EPS that missed estimates by $0.05, leading to a drop in share price.
What is the current stock price of Treace Medical Concepts?
As of November 1, the stock price of Treace Medical Concepts is $4.78.
What is the analyst rating for Treace Medical Concepts?
Treace Medical Concepts has a consensus rating of Neutral among analysts.
How does Treace Medical Concepts compare to its competitors?
Compared to its competitors, Treace Medical Concepts ranks lower in revenue growth and gross profit, indicating room for improvement.